Published in CNS Drugs on January 01, 2005
Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice. Ann Gen Psychiatry (2014) 0.84
Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. BMC Psychiatry (2012) 0.81
Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry (2008) 0.76
Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. Schizophr Bull (2017) 0.75
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry (2004) 1.82
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
Osteoporosis in patients with schizophrenia. Am J Psychiatry (2005) 1.58
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry (2003) 1.46
Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand (2006) 1.44
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry (2004) 1.25
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2012) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Factors influencing compliance in schizophrenia patients. J Clin Psychiatry (2003) 1.16
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry (2004) 1.13
Brain activation patterns during a selective attention test--a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Res (2006) 1.11
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol (2004) 1.10
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
Gender differences in regional cerebral activity during the perception of emotion: a functional MRI study. Neuroimage (2006) 1.08
Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res (2005) 1.07
Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs (2012) 1.06
Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry (2005) 1.05
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Various bilateral olfactory deficits in male patients with schizophrenia. Schizophr Bull (2005) 1.04
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Res (2003) 1.01
Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin Exp Res (2003) 1.01
An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. Am J Psychiatry (2003) 1.01
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res (2009) 1.00
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res (2013) 0.97
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol (2012) 0.95
No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res (2004) 0.95
Language lateralization in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Psychiatry Res (2006) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry (2003) 0.92
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs (2013) 0.92
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res (2005) 0.91
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry (2002) 0.91
Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res (2005) 0.91
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol (2010) 0.90
Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry (2003) 0.90
Brain activation patterns during a verbal fluency test-a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophr Res (2004) 0.90
The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology (2007) 0.89
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2011) 0.88
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol (2012) 0.88
Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Am J Psychiatry (2003) 0.87
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry (2005) 0.85
The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
Comparison of three methods for detecting Campylobacter spp. in chilled or frozen meat. Int J Food Microbiol (2005) 0.84
Facial emotion recognition and its relationship to subjective and functional outcomes in remitted patients with bipolar I disorder. Bipolar Disord (2011) 0.84
Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol (2010) 0.84
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. Int Clin Psychopharmacol (2014) 0.83
Poor health behaviour and reduced quality of life of people treated with psychotropic drugs. Hum Psychopharmacol (2011) 0.82
Emerging drugs for schizophrenia. Expert Opin Emerg Drugs (2011) 0.82
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res (2009) 0.82
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr Res (2007) 0.82
The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) (2002) 0.81
Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol (2010) 0.81
Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol (2011) 0.81
Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry (2013) 0.80
Executive function and memory in relation to olfactory deficits in alcohol-dependent patients. Alcohol Clin Exp Res (2006) 0.80
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses (2010) 0.80
Management of a risperidone-induced tardive Pisa syndrome: a case report. J Clin Psychopharmacol (2012) 0.80
Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. Soc Psychiatry Psychiatr Epidemiol (2010) 0.80
Olfactory functioning in patients with alcohol dependence: impairments in odor judgements. Alcohol Alcohol (2004) 0.79
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res (2005) 0.79
Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol (2006) 0.79
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol (2006) 0.79
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol (2005) 0.79
Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol (2006) 0.79
Alcohol and/or benzodiazepine use: different accidents--different impacts? Hum Psychopharmacol (2005) 0.78
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2009) 0.78
Alcohol and benzodiazepines in falls: an epidemiological view. Drug Alcohol Depend (2005) 0.78
The generic alternative in schizophrenia: opportunity or threat? CNS Drugs (2004) 0.78
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essent Psychopharmacol (2005) 0.78
Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. J Clin Psychopharmacol (2013) 0.78
Neural substrates for episodic encoding and recognition of unfamiliar faces. Brain Cogn (2007) 0.77
The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. Int J Neuropsychopharmacol (2003) 0.77
Psychiatric disorders and the ICU: gaps and opportunities. Intensive Care Med (2008) 0.77
Schizophrenia: when clozapine fails. Curr Opin Psychiatry (2015) 0.77
Alcohol and/or benzodiazepine use in injured road users. Hum Psychopharmacol (2003) 0.77